NasdaqGS:PHVSPharmaceuticals
Pharvaris (PHVS) Is Up 9.1% After Deucrictibant Shows 92% HAE Attack Reduction and Phase 3 Update
Pharvaris recently announced third-quarter 2025 earnings, reporting a net loss of €37.14 million and outlined clinical progress for its hereditary angioedema (HAE) candidate deucrictibant, including long-term safety data and an anticipated pivotal Phase 3 study readout in 2026.
The new data presented showed an average 92.4% reduction in HAE attacks over 34 months and highlighted a plasma kinin biomarker assay that may help further characterize bradykinin-mediated angioedema.
We’ll explore...